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Xanthine oxidase (XO) is an enzyme in the purine salvage pathway that catalyzes the oxidation 
of hypoxanthine to xanthine with subsequent production of uric acid from the xanthine 
oxidation, and it has been considered an important target of newly developed inhibitors. Based 
on the advantages of using immobilized capillary enzyme reactors (ICERs) in a 2D LC system 
as a tool for screening new enzymatic ligands, this work validated an XO-ICER using 
allopurinol as a positive control. Despite the complex interaction between XO and allopurinol 
due its tight binding nature, it was possible to recognize the inhibitory kinetics parameters 
through Morrison’s equation. The tight binding nature of inhibition was established by varying 
the IC50 values according to the substrate concentration. The kinetic inhibitory profile of 
allopurinol was used to validate the XO-ICER. Then, the XO-ICER was used to screen specific 
ruthenium derivatives. The selected compound, 4CBALO, an allopurinol ruthenium derivative, 
exhibited 100% inhibition at 200 µM compared to 86% inhibition from allopurinol at the same 
concentration. The inhibitory effect on the immobilized XO was reversible after the elution of 
the compound, with immediate recovery of the ICER activity. Additionally, 4CBALO behaved 
as a selective and competitive tight binder of xanthine oxidase with a true Ki value of 0.29 µM, 
which was obtained from the Morrison equation. This report describes the first on-flow 
characterization of tight binders of xanthine oxidase. 
 
 
 
 
 
 
 
 
1. Introduction 
The multidimensional high performance liquid chromatography (2D 
LC) has been a powerful tool for screening and characterization of 
enzymatic inhibitors in the search of new bioactive molecules.1-3 
Among several approaches, the use of immobilized capillary reactors 
(ICERs) in the first dimension of the chromatographic system has 
guaranteed reliability of results  when compared with off-line 
enzymatic assays, due to fact that, among other applications, the 
generated product can be expressed as enzymatic activity.1 For 
classical binders this technique has been successfully used in their 
characterization,1,4 however, for compounds with more complex 
inhibition mechanism such as tight binders, the use of ICER has not 
yet been explored. 
Xanthine oxidase (XO) is an important target for the 
development of antihyperuricemic drugs, which help decrease uric 
acid production (Figure 1). This enzyme also generates reactive 
oxygen species (ROS) that have been associated with certain 
pathophysiological processes, such as post-ischemic reperfusion 
injury, diabetes and chronic heart failure.5 The XO inhibitor, 
allopurinol, was approved by the Food and Drug Administration 
(FDA) in 1966 and, in spite of its side effects, has been used for gout 
treatment since then.  
 
Figure 1 here 
 
Allopurinol is not only an inhibitor of but also a substrate for 
XO, and its oxidation product, oxypurinol, is also an inhibitor of the 
enzyme. The nature of its inhibition, however, is quite different from 
that of allopurinol. Although the apparent inactivation of XO is 
caused by allopurinol in the absence or presence of xanthine, 
oxypurinol requires the substrate.6,7  
For these compounds, which are known as tight-binding 
inhibitors, the steady state approximation model and the use of 
double reciprocal graphics are not valid. This is because, under 
equilibrium conditions, these inhibitors cause depletion of the non-
bound form of the inhibitor by the formation of the enzyme-inhibitor 
complex.8,9  
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This type of inhibitors offers a special challenge to its 
characterization since it requires different methods of analysis. 
The simplest way to determine that a tight binding inhibition is 
occurring is through an inhibitors dose-response curve. An IC50 
value similar to the total enzyme concentration (within a factor of 
10) is a good hint of this type of inhibition.8 
Thus, a straightforward procedure for determining the Ki
app for 
tight binder inhibitors is to measure the IC50 at a fixed concentration 
of the substrate and with a variety of enzyme concentrations and 
then plot the obtained IC50 versus total enzyme concentration. The 
results of these data can be fitted to a linear equation and the y-
intercept provides an estimate of Ki. The major limitation of this 
approach is one’s ability to accurately determine the y-intercept of a 
plot with a data containing typical levels of experimental error.5  
Nevertheless, this well settled approach is not feasible when 
using an on-flow assay with an immobilized enzyme; therefore, the 
adopted procedure has been to determine IC50 values for these tight 
binders at a wide range of substrate concentrations with Ki
app  
determined by the Morrison equation.8  
This wide range of substrate concentrations is required to avoid 
misinterpretation of results, because the tight binding inhibitors 
exhibits double reciprocal plots similar to classical non-competitive 
inhibition pattern. The initial concentration of a double reciprocal 
plot, obtained only at extreme conditions (higher substrate 
concentrations and higher inhibitor concentrations), allows 
evidencing the nonlinearity portion of the double reciprocal plot and, 
thus, the selection of the best method for obtaining concentration-
response data for tight binders. For this approach, the total enzyme 
concentration is needed. Fortunately, for tight binding inhibitor this 
is a feasible highly accurate measurement. 8 
In this context, to the best of our knowledge, this is the first 
report describing an on-flow assay for XO tight inhibitors using 
allopurinol as a reference binder. Furthermore, the developed 2D LC 
assay was used to screen and characterize five ruthenium complexes 
that were synthesized and characterized by the following techniques: 
elemental analysis, NMR (31P and 1H), UV-Vis, infrared, 
electrochemical and X-ray crystallography (Figure 2).10 
 
Figure 2 here 
 
An approach to the discovery of new metallodrugs involves binding 
of an organic compound of known therapeutic activity to a metal-
containing fragment; this results in a metal-drug synergism in which 
the metal acts as a carrier and stabilizer for the drug until it reaches 
its target. Such combined effects may result in an important 
enhancement of the activity of the drug. Thus, for the screening 
assay with the XO-ICER we selected a series of five ruthenium (II) 
complexes. All five complexes present in their structure a 
bisphosphinic ligand, dppb (1,4-bis(diphenylphosphino)butane), one 
chloride, one diimine ligand and a ligand L. The L ligands used were 
either allopurinol or imidazole or benzimidazole.  As shown in 
Figure 2, the complexes: CBALO, 4CBALO and 5CBALO, each has 
one molecule of allopurinol as the ligand. These allopurinol analogs 
differ with respect to the diimine ligands, 2’2-bipyridine, 4,4’-
dimethyl-2,2’-bipyridine and 5,5’-dimethyl-2,2’-bipyridine. 
Additionally, two ruthenium complexes with imidazole (CBIM) and 
benzoimidazole (CBZM) were also tested. The on-flow assay would 
furnish a comparison in the inhibition effect produced by the three 
series of allopurinol ruthenium (II) complexes and the imidazole 
(CBIM)  or benzimidazole (CBZM) complexes. Furthermore, the 
influence regarding the position of in which the ruthenium 
coordinates with allopurinol would also be evaluated. This 
information is important for our ongoing research with respect to the 
mechanism of action in the inhibition process of the enzyme for the 
production of uric acid. Besides, Ru(II)/N-heterocyclic  complexes 
are stable, both, in solid state, and in solution. 
2. Experimental 
 
2.1 Chemicals and materials 
 
Xanthine oxidase (EC 1.17.3.2) grade I ammonium sulfate 
suspension from bovine milk, xanthine, uric acid, allopurinol, 
ammonium formate, 25% glutaraldehyde solution in water (grade II) 
and (3-aminopropyl) triethoxysilane (APTS) were purchased from 
Sigma (St. Louis, MO, USA). The 9-deazaguanine derivate (BCX-
762) was synthesized and kindly supplied by scientists at BioCryst 
Pharmaceuticals. The expression and purification of purine 
nucleoside phosphorylase from human (HsPNP) were performed as 
reported by Semeraro et al.,11 and it was prepared at 2.1 mg/mL in 
Tris-HCl buffer (pH 7.0). Methanol (HPLC grade) was from J.T. 
Baker (Xalostoc, MC, Mexico). Formic acid from Fluka, solvents 
and all other chemicals not mentioned above were of analytical 
grade. The mobile phases were prepared daily with ultrapure water 
obtained from a Milli-Q system (Millipore, São Paulo, Brazil) and 
were filtered through a PVDF membrane (0.45 µm) purchased from 
Millipore. The silica-fused capillaries (30 cm x 0.364 mm, 0.07 mm 
i.d.) that were used for the preparation of the ICERs were provided 
by Polymicro Technologies (Phoenix, AZ, USA).  
 
 
2.2 Apparatus  
 
XO-ICERs were produced using a syringe pump Harvard Apparatus 
11 Plus.  
Analytical columns were packed using the ascending slurry 
method at 7500 psi using methanol for the slurry preparation (50 
mL) and for packing. Afterwards, the column was conditioned with 
methanol at a 1.0 mL min−1 flow rate for 12 h.  
Chromatographic analyses were performed using a Shimadzu 2D 
LC system (Shimadzu, Kyoto, Japan), which consisted of two LC-20 
AD pumps, a CBM-20A controller, an SIL-20 A autosampler, an 
SPD-20 A UV-Vis detector and a VICI six-way switching valve that 
was used to select the solvent. Figure 3 illustrates the 2D LC system 
used. 
   
Figure 3 here 
 
 
2.3 Chromatographic conditions  
 
The xanthine oxidase enzymatic reaction was conducted on-flow 
with the XO-ICER using 10 mM ammonium formate, pH 7.4, at 
0.05 mL/min (first dimension). The chromatographic separations 
were performed in the second dimension using a home-made packed 
Luna® C18 (150 x 4.6 mm; 10 µm) analytical column with 10 mM 
ammonium formate, pH 4.0/ methanol (99:1 v/v) at 0.6 mL/min as 
the mobile phase. Dual mode detection was used for uric acid and 
xanthine at 294 and 260 nm, respectively. 
The chromatographic conditions used during the selectivity 
assay with HsPNP were the same as previously published.12  
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2.4 ICERs Preparation  
 
The immobilization of XO and HsPNP were based on previously 
reported procedures4,12 with minor adjustments. The glutaraldehyde 
space linker was used at a concentration of 0.25%. Additionally, to 
improve the enzyme immobilization, the syringe pump flow rate was 
adjusted to only 50 µL/min.  
For the immobilization of HsPNP, 1 mL of the enzyme solution 
(2.1 mg/mL protein in Tris-HCl buffer, pH 7.0) was dialyzed at 4°C 
against phosphate buffer (50 mM, pH 7.0).  
The ICERs were stored at 4°C in the activity enzymatic buffer 
(first dimension eluents).  
 
 
2.5 Method validation 
 
Uric acid solutions were prepared, in triplicate, from 0.4 to 40 µM 
for the calibration curve. The solutions were transferred to a vial, 
and 10 µL of each solution was injected into an empty capillary 
connected to the first dimension of the chromatographic system. The 
intra- and inter-day precision and accuracy of the method were 
evaluated by analyzing quality control samples at three levels of 
concentration (0.7, 15 and 37 µM). Five samples of each 
concentration were prepared and analyzed on 3 nonconsecutive days.  
The acceptance criteria for the limit of quantification mandated 
that the precision of three samples had less than 20% variability, 
whereas the limit of detection was estimated as the concentration 
that produced a signal-to-noise ratio of 3. 
 
 
2.6 Kinetics studies 
 
The enzymatic activity was evaluated by quantifying the uric acid 
that was produced from the oxidation of xanthine by the XO-ICERs 
at 294 nm.  
Solutions with xanthine concentrations ranging from 1.0 to 500 
µM were injected in duplicate. Michaelis-Menten plots were used to 
evaluate KM via nonlinear regression analysis using Origin software 
version 9.0. 
ICER stability was determined from the ICER production of uric 
acid by injecting 10 µL of 200 µM xanthine, in duplicate, over a 
period of 60 days. 
 
 
2.7 Screening study 
 
Five ruthenium complexes (Figure 3) synthesized and characterized 
in accordance with reported procedures10 were screened with the 
XO-ICERs. Stock solutions of each complex were first prepared in 
methanol at a concentration of 2.0 mM. Preliminary studies showed 
that the use of 10-20% of methanol had no significant effect on the 
XO-ICER activity; therefore, a solution containing 10% v/v of 
methanol was chosen for the final dilution. 
The compounds were evaluated at concentrations of 200 µM by 
injecting 10 µL of a solution containing 25 µM xanthine. The 
inhibition percentage was calculated by comparing the uric acid 
concentration obtained in the absence and presence of the 
complexes. Moreover, the reversibility of the XO inhibition was 
studied by determining the enzymatic activities of the XO-ICER 
before and after the elution of the solutions containing the complexes 
(200 µM).  
 
 
2.8 Determination of mechanism of inhibition 
 
The inhibition mechanism was determined by plotting the IC50 
values against the substrate concentration, expressed as the 
[substrate]/KM. To determine each IC50, the fixed concentrations of 
xanthine were 32, 128, 320, 384 and 512 µM with varying 
concentrations of allopurinol in the range of 0.0075 to 4 µM. The 
series of IC50 values for 4CBALO were determined in the 0.01 to 
2.56 M concentration range at the following fixed concentrations of 
xanthine: 32, 96, 128, and 256 µM.  
The IC50 values for allopurinol and 4CBALO were obtained by 
plotting the percentage inhibition versus the inhibitor concentration 
using Origin 9.0 software. 
The Morrison equation (Eq.1) was used to calculate the 
inhibition constant Ki
app through a dose-response curve that was 
calculated using GraphPad Prism software. To calculate the dose-
response curve, the enzymatic activity was determined at 25 µM of 
xanthine and different concentrations of either allopurinol (0.3 to 1.8 
µM) or 4CBALO (0.08 to 3.0 µM). 
 The total enzyme concentrations were estimated by 
extrapolating the linear portion of the dose-response curve to the (x) 
axis.8  
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In the Morrison equation (Eq. I), vi/vo represents the enzyme 
activity, whereas [E]T is the total enzyme concentration, [I]T is the 
total inhibitor concentration, and Ki
app is the apparent inhibition 
constant. The true inhibition constant (Ki) is obtained using a 
different equation in accordance with the inhibitor type. 
 
 
3. Results and discussion 
 
 
3.1 XO-ICER preparation and kinetics parameters  
 
Zonal bioaffinity chromatography has previously been successfully 
used for ICERs characterization through Michaelis-Menten 
parameters by means of a 2D LC system.1,2 Herein, an XO-ICER 
was prepared and used in the first dimension of a 2D LC system 
(Figure 3) to not only determine its kinetic parameters but also fully 
characterize its tight-binding inhibitors. The validated LC method 
was used to quantify the production of uric acid by the ICERs. With 
regard to validation, the method provided a linear response (r = 
0.9997) for uric acid production over a concentration range of 0.4 to 
40 µM. Additionally, the intermediate precision, measured as the 
CV, was ≤ 5.1%, with results ranging from 97.3 to 114% accuracy. 
The limit of quantification and detection were 0.4 and 0.2 µM, 
respectively.  
The immobilization of XO is not trivial, and, although 
immobilization was achieved by means of the Schiff´s base approach 
with good enzymatic performance, the immobilization conditions 
were carefully examined. Firstly, the glutaraldehyde (used as spacer) 
concentration was decreased from 1% to 0.25% v/v. This was done 
to prevent polymerization inside the capillaries, which would lead to 
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flow obstruction and, the extensive crosslinking of the enzyme 
during the immobilization. 
Additionally, the flow-rate of the syringe-pump was also evaluated 
as a mean to maximize reaction time. The flow-rate of 50 µL/min 
furnished the highest enzymatic activity for the XO-ICER. 
For the 2D LC assay, the phosphate buffer used in the solution assay 
for XO 1 was replaced, without impairing the enzymatic activity, by 
ammonium formate, without changing the pH of the solution, but at 
a lower molar concentration. 
The activities of the XO-ICERs prepared over 2 months were 
reproducible with a CV=2.18% (n=7). Furthermore, The XO-ICERs 
activity was maintained over 60 days by storing them at 4˚C.The 
chromatogram in Figure 4 illustrates the XO-ICERs production of 
uric acid under the activity assay conditions evaluated.  
 
Figure 4 here 
 
The experimental data of the XO-ICER activity obtained from 
xanthine concentrations ranging from 1 to 800 µM were fitted using 
a nonlinear regression analysis resulting in a KM value of 23.26±3.88 
µM. This value of KM shows a decrease in activity when compared 
to a reported KM value obtained from a solution assay of xanthine 
oxidase from bovine milk (KM = 8.00 ± 1)
13.  This is, however, of 
non-concern since the activity of the XO-ICER was maintained for a 
long period, allowing a series of experiments. It must be noticed that 
oxidation reaction occurs on flow, and in this the contact time 
between the enzyme and the substrate is shorter. Furthermore, 
allopurinol, a reference inhibitor, was characterized by the XO-ICER 
demonstrating that the molecular recognition was not affected. 
 
 
3.2 XO-ICER validation in ligand screening assay 
 
Allopurinol was selected as the reference inhibitor for the purposes 
of validating the XO-ICER on-flow screening assay for tight-binding 
inhibitors.6 Under the assay conditions, an 86% inhibition was 
achieved with 200 µM allopurinol. A graph of the IC50 value as a 
function of substrate concentration was plotted to characterize the 
inhibition mode (Figure 5A).8 In agreement with published results,7 
the data obtained indicated that allopurinol was a competitive 
inhibitor. 
 Moreover, Morrison’s plot (Figure 5B) was used to obtain a 
Ki
app of 3.25±0.37 µM. Because allopurinol is a competitive tight-
binding enzyme inhibitor, Eq. II was used to furnish a Ki value of 
1.55 µM. In Eq. II, Ki is the true inhibition constant, [S] is the 
substrate concentration and KM is the Michaelis-Menten constant.
8 
The active enzyme concentration value of 4.5 µM was estimated 
from the dose-response plot obtained with a 25 µM substrate 
concentration  
 
)
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K
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The Ki value obtained here (Figure 5B) was in the same order of 
magnitude of that of a previously published work (6.3 µM),7 thus 
validating the 2D LC XO-ICER screening assay for tight-binding 
inhibitors.  
 
Figure 5 here 
 
 
3.3 Screening assay 
 
Five ruthenium complexes (Figure 3) were screened using the 
validated XO-ICER on-flow assay conditions, and the obtained 
results are graphically illustrated in Figure 6.  
Because XO inhibitors can affect the purine pathway, and 
because selectivity plays a crucial role in selecting enzyme 
inhibitors, the three most XO-ICER-active ruthenium complexes 
were also evaluated with the HsPNP-ICER.12 With the HsPNP-
ICER, compound BCX-762 was used as a reference inhibitor.14 The 
results demonstrated a high selectivity index of the tested complexes 
towards XO (Figure 6). 
 
Figure 6 here 
 
 
Additionally, the reversibility of the XO inhibition by 4CBALO 
and 5CBALO was evaluated by determining the XO-ICER activity 
immediately before and after the injection of both inhibitors. The 
XO-ICER activity was readily recovered (97%) with 4CBALO, but 
the ICER activity did not recover with 5CBALO, suggesting, for the 
latter, an irreversible inhibition or a slow tight binder.15 For this 
reason, 4CBALO was selected for investigation of its mechanistic 
modality.  
As expected for an allopurinol derivative, a tight binder behavior 
was found for 4CBALO towards XO-ICER. Reversible tight-binding 
inhibitors exert their effects on enzyme-catalyzed reactions at low 
concentrations, i.e., comparable to the concentration of the enzyme 
(within a factor of 10). Therefore, the results obtained for allopurinol 
([E]T = 5.0 µM and IC50= 0.32 µM) and 4CBALO ([E]T = 0.5 µM 
and IC50= 0.07 µM) corroborated the assigned mechanistic modality. 
From the obtained data, 4CBALO was characterized as a 
competitive inhibitor with Ki
app and Ki values of 0.60 ± 0.07 and 
0.29 µM, respectively. 
 
     
 
4. Conclusions 
The produced XO-ICER showed high stability with good 
reproducibility following preparation. The complete 
chromatographic separation of xanthine (the substrate) from uric 
acid (XO oxidation product) in the second dimension of a 2D LC 
system resulted in the development of a zonal bioaffinity 
chromatographic assay that was efficiently used to not only screen 
XO tight binder inhibitors but also fully characterize their inhibition 
modalities. From the developed assay, a series of five ruthenium 
allopurinol derivatives complexes were screened and the 4CBALO 
was identified as a competitive tight-binding inhibitor of XO with a 
tighter inhibition constant than the one found for allopurinol: 
Ki
4CBALO = 0.29 µM; Ki
allopurinol = 1.55 µM. 
The great advantage of this fully automatized method is that not 
only the kinetics parameters is easily determined, but also the search 
for inhibitors are facilitated in as much as that the same 
chromatographic conditions can be used for screening and for the 
inhibition mechanism studies. With an assay condition of less than 
17 min, 84 analyses can be carried out in a single day. Moreover, the 
same XO-ICER was continually used for about 2 months.  
To our knowledge, this is the first time that a zonal bioaffinity 
chromatographic assay was used to mechanistically characterize 
tight-binding inhibitors, providing a comprehensive application of 
this assay model. 
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Legends of Figures 
 
Fig. 1 Reactions catalyzed by xanthine oxidase. 
  
Fig. 2 General chemical structure of screened ruthenium complexes. CBALO: R1 = R2 = H (2,2’-bipyridine); L = 
allopurinol. 4CBALO: R1 = H; R2 = CH3 (4,4’-dimethyl-2,2’-bipyridine) ; L = allopurinol. 5CBALO: R1 = CH3; R2 = 
H (5,5’-dimethyl-2,2’-bipyridine); L = alopurinol. CBIM: R1 = R2 = H (2,2’-bipyridine); L = imidazole. CBZM: R1 = 
R2 = H (2,2’-bipyridine); L = benzimidazole. 
  
Fig. 3  Schematic representation of 2D LC chromatographic system 
  
Fig. 4 Chromatogram of uric acid production by XO-ICER from xanthine, 160 µM, at 294 nm 
  
Fig. 5 (a) The effects of substrate concentration on the IC50 values, showing a competitive inhibition of allopurinol; 
(b) Plot of enzymatic activity (uric acid produced) as a function of inhibitor concentration for allopurinol. The solid 
curve drawn through the data points represents the best fit to the Morrison equation 
  
Fig. 6 Graphical results of the screening and selectivity assays  
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Fig. 1 Reactions catalyzed by xanthine oxidase.  
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Fig. 2 General chemical structure of screened ruthenium complexes. CBALO: R1 = R2 = H (2,2’-bipyridine); 
L = allopurinol. 4CBALO: R1 = H; R2 = CH3 (4,4’-dimethyl-2,2’-bipyridine) ; L = allopurinol. 5CBALO: R1 = 
CH3; R2 = H (5,5’-dimethyl-2,2’-bipyridine); L = alopurinol. CBIM: R1 = R2 = H (2,2’-bipyridine); L = 
imidazole. CBZM: R1 = R2 = H (2,2’-bipyridine); L = benzimidazole.  
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Fig. 3 Schematic representation of 2D LC chromatographic system  
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Fig. 4 Chromatogram of uric acid production by XO-ICER from xanthine, 160 µM, at 294 nm  
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Fig. 5a  The effects of substrate concentration on the IC50 values, showing a competitive inhibition of 
allopurinol;  
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Fig. 5b  Plot of enzymatic activity (uric acid produced) as a function of inhibitor concentration for allopurinol. 
The solid curve drawn through the data points represents the best fit to the Morrison equation  
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Fig. 6 Graphical results of the screening and selectivity assays  
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On-flow characterization of tight binders of xanthine oxidase.  
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